- Home
- LSBK vs CUE Comparison
LSBK vs CUE Comparison
Compare LSBK & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSBK | CUE |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 233.5M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LSBK | CUE |
|---|---|---|
| Price | $17.38 | $27.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 8.5K | ★ 173.1K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | 49.23 | ★ 61.11 |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.11 | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $12.50 | $0.17 |
| 52 Week High | $17.96 | $45.50 |
Technical Indicators
Market Signals| Indicator | LSBK | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 63.94 | 49.11 |
| Support Level | $16.68 | $24.35 |
| Resistance Level | $17.56 | $33.95 |
| Average True Range (ATR) | 0.09 | 3.41 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 89.16 | 40.84 |
Price Performance
Historical ComparisonAbout LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.